1. Introduction {#sec1-nutrients-09-00595}
===============

The liver is the pivotal organ for metabolism and it metabolizes carbohydrates, lipids, and proteins, which are the so-called "three major nutrients" \[[@B1-nutrients-09-00595],[@B2-nutrients-09-00595],[@B3-nutrients-09-00595],[@B4-nutrients-09-00595]\]. Liver cirrhosis (LC) is an end-stage form in liver diseases and LC is characterized by several metabolic or nutritional disorders and portal hypertension-related complications such as ascites or varices, all of which can lead to dismal clinical outcome \[[@B1-nutrients-09-00595],[@B2-nutrients-09-00595],[@B3-nutrients-09-00595],[@B4-nutrients-09-00595]\]. Over the past two or three decades, numerous clinical and biochemical predictors have been proposed in an effort to more accurately predict the prognosis in LC patients and evaluate their short and long-term survival correctly \[[@B5-nutrients-09-00595],[@B6-nutrients-09-00595],[@B7-nutrients-09-00595],[@B8-nutrients-09-00595],[@B9-nutrients-09-00595]\]. The Child-Pugh scoring system and the Model for End-stage Liver Disease (MELD) scoring system are two major prognostic scoring systems in LC patients \[[@B5-nutrients-09-00595],[@B6-nutrients-09-00595],[@B7-nutrients-09-00595],[@B8-nutrients-09-00595],[@B9-nutrients-09-00595]\]. In particular, the MELD score is calculated by three easily available and reproducible laboratory tests and is useful for predicting outcomes for patients undergoing liver transplantation (LT) \[[@B5-nutrients-09-00595]\]. In our country, LT is not common due to the shortage of transplanted liver and the Child-Pugh scoring system has been preferably used for assessing prognosis in LC patients.

Sarcopenia is a clinical entity as determined by skeletal muscle mass loss and decline of muscle strength and this clinical entity has recently drawn much attention among clinicians owing to its significant deleterious impact on outcomes \[[@B10-nutrients-09-00595],[@B11-nutrients-09-00595],[@B12-nutrients-09-00595],[@B13-nutrients-09-00595],[@B14-nutrients-09-00595],[@B15-nutrients-09-00595],[@B16-nutrients-09-00595]\]. LC can be associated with secondary sarcopenia because of protein metabolic disorder and/or energy metabolic disorder \[[@B11-nutrients-09-00595],[@B14-nutrients-09-00595],[@B15-nutrients-09-00595]\]. Skeletal muscle mass loss can be linked to poorer clinical outcomes in LC patients, hepatocellular carcinoma (HCC) patients, or patients with other malignancies \[[@B17-nutrients-09-00595],[@B18-nutrients-09-00595],[@B19-nutrients-09-00595],[@B20-nutrients-09-00595],[@B21-nutrients-09-00595],[@B22-nutrients-09-00595],[@B23-nutrients-09-00595],[@B24-nutrients-09-00595],[@B25-nutrients-09-00595],[@B26-nutrients-09-00595]\]. Skeletal muscle mass can be assessed by computed tomography (CT), magnetic resonance imaging (MRI), dual energy X-ray absorptiometry and bioimpedance analysis (BIA), which are consistent and accurate assessment modalities \[[@B14-nutrients-09-00595],[@B15-nutrients-09-00595],[@B17-nutrients-09-00595],[@B19-nutrients-09-00595],[@B27-nutrients-09-00595],[@B28-nutrients-09-00595]\]. Among these modalities, BIA is particularly attractive since it can noninvasively determine body composition analysis in LC patients \[[@B14-nutrients-09-00595],[@B15-nutrients-09-00595],[@B17-nutrients-09-00595],[@B19-nutrients-09-00595],[@B27-nutrients-09-00595],[@B28-nutrients-09-00595]\].

However, which of two prognostic markers (i.e., the Child-Pugh scoring system and skeletal muscle mass) has stronger influence on clinical outcomes in patients with LC remains unclear. Addressing these questions may be clinically of significance. The aim of this study was to investigate the influence of skeletal muscle mass as determined by data in BIA on survival compared with the Child-Pugh score in patients with LC.

2. Patients and Methods {#sec2-nutrients-09-00595}
=======================

2.1. Patients {#sec2dot1-nutrients-09-00595}
-------------

The current study was a single center retrospective study. Between October 2005 and October 2015, a total of 529 LC individuals with BIA data available were admitted at the Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. In our department, BIA (Inbody 720, Tokyo, Japan) was routinely performed in the resting and standing position principally on an outpatient basis for patients who consented to nutritional evaluation. In this analysis, skeletal muscle mass was evaluated using BIA data. Of these patients, patients with severe ascites (*n =* 24) were excluded from this study as body weight, body mass index (BMI), and skeletal muscle mass index (SMI) using BIA may be overestimated in these patients \[[@B29-nutrients-09-00595],[@B30-nutrients-09-00595]\]. Twenty-three subjects had been lost to follow-up within one year after performing BIA and they were excluded from this analysis for avoiding bias. In the remaining 482 subjects, 99 had HCC on radiological findings at baseline and they were also excluded because presence of HCC can affect the interpretation of BIA data. A total of 383 subjects were therefore analyzed in the current study. Follow-up observation after BIA included periodical blood tests, radiological assessments by ultrasonography (US), CT, or MRI in order to detect HCC incidence every 3--6 months. There was no patient who underwent LT during observation period. LC was diagnosed using pathological findings, radiological findings such as US, CT, or MRI and/or laboratory data including liver fibrosis markers \[[@B31-nutrients-09-00595],[@B32-nutrients-09-00595],[@B33-nutrients-09-00595]\]. In patients with lower serum albumin level (less than 3.5 g/dL), liver supporting therapies including branched-chain amino acid (BCAA) treatment or late evening snack with BCAA enriched snacks were in consideration \[[@B4-nutrients-09-00595],[@B34-nutrients-09-00595],[@B35-nutrients-09-00595]\]. In patients with hepatitis virus-related LC, antiviral treatments including direct acting antivirals, interferon-based regimens or nucleoside analogues therapy were also in consideration \[[@B4-nutrients-09-00595],[@B34-nutrients-09-00595]\]. SMI was calculated as reported elsewhere \[[@B28-nutrients-09-00595]\]. Briefly, SMI was defined as "appendicular skeletal muscle mass/(height (m))^2^" \[[@B28-nutrients-09-00595]\]. We retrospectively investigated the influence of SMI on survival in males and females, as compared with Child-Pugh scores, which was well established prognostic marker \[[@B7-nutrients-09-00595],[@B8-nutrients-09-00595],[@B9-nutrients-09-00595]\]. In terms of the comparison of the effects of SMI and other markers on survival, we used time-dependent receiver operating characteristics (ROC) analysis \[[@B36-nutrients-09-00595]\]. We also investigated parameters associated with overall survival (OS) in the univariate and multivariate analyses. HCC diagnosis and treatment choices for HCC were as reported elsewhere \[[@B37-nutrients-09-00595],[@B38-nutrients-09-00595]\].

The ethical committee meeting in Hyogo College of Medicine acknowledged the current study protocol and this study strictly followed all regulations of the Declaration of Helsinki.

2.2. Statistical Analyses {#sec2dot2-nutrients-09-00595}
-------------------------

Categorical parameters were compared by Fisher's exact test. Continuous parameters were compared by unpaired *t*-test, Mann-Whitney *U* test, or Kruskal-Wallis test, as applicable. In continuous parameters, ROC curve analysis for survival was conducted for the purpose of setting the optimal cutoff point that is linked to maximal sum of specificity and sensitivity and we classified continuous parameters into two groups using these cutoff points, which was then treated as dichotomous covariates in the univariate analysis. Survival curve was created by using the Kaplan-Meier method and compared in the log-rank test. Parameters with *p* value \< 0.05 in the univariate analysis were finally subjected to the multivariate analysis in the Cox proportional hazards model. OS was defined as the time interval from the date of performing BIA until death from any cause or the last follow-up visit. Additionally, we analyzed time-dependent ROC curves of SMI, Child-Pugh scores, and variables which revealed to be significant in the multivariate analysis for survival, and compared between area under the ROCs (AUROCs) for above parameters in each time point (two-, three-, four-, five-, six-, and seven-years) \[[@B36-nutrients-09-00595]\].

Data are shown as the average ± standard deviation (SD) unless otherwise mentioned. Statistical significance was set at *p* \< 0.05. Statistical analysis was performed with the JMP 11 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-nutrients-09-00595}
==========

3.1. Baseline Characteristics {#sec3dot1-nutrients-09-00595}
-----------------------------

The baseline characteristics of the analyzed subjects (*n =* 383) are presented in [Table 1](#nutrients-09-00595-t001){ref-type="table"}. They included 205 males and 178 females with an average ± SD age of 65.2 ± 10.3 years. The median follow-up periods were 3.2 years (range: 0.2--10.7 years). The average ± SD value in SMI for male was 7.4 ± 0.9 cm^2^/m^2^ whereas that for female was 6.0 ± 0.7 cm^2^/m^2^ (*p \<* 0.0001). According to the Asian Working Group for Sarcopenia criteria (AWGS), the cut-off values for SMI are 7.0 kg/m^2^ for male and 5.7 kg/m^2^ for female. \[[@B28-nutrients-09-00595]\] The proportion of decreased SMI (D-SMI: less than each cutoff value as defined by AWGS criteria) in male was 36.1% (74/205) and that in female was 34.8% (62/178). A total of 136 patients (35.5%) had D-SMI. As for Child-Pugh scores, five points was in the majority, both in males (51.7%, (106/205)) and females (44.9%, (80/178)). In males, SMI significantly correlated with age (overall significance, *p* \< 0.0001), while in females it did not (overall significance, *p =* 0.1921) ([Figure 1](#nutrients-09-00595-f001){ref-type="fig"}A,B). In both males and females, SMI significantly correlated with BMI (*p* values, both \<0.0001) ([Figure 1](#nutrients-09-00595-f001){ref-type="fig"}C,D). In both males (*p =* 0.3716) and females (*p =* 0.1330), SMI did not significantly correlate with the Child-Pugh classification ([Figure 1](#nutrients-09-00595-f001){ref-type="fig"}E,F).

3.2. Cumulative OS Rates for the Entire Cohort, Male and Female According to SMI {#sec3dot2-nutrients-09-00595}
--------------------------------------------------------------------------------

For the entire cohort (*n =* 383), the one-, three-, and five-year cumulative OS rates were 92.7%, 82.4%, and 59.2%, respectively, in patients with D-SMI, and 97.2%, 92.2%, and 84.4%, respectively, in patients without D-SMI (*p \<* 0.0001) ([Figure 2](#nutrients-09-00595-f002){ref-type="fig"}). For males (*n =* 205), the one-, three-, and five-year cumulative OS rates were 91.9%, 78.0%, and 53.6%, respectively, in patients with D-SMI, and 96.2%, 92.0%, and 84.7%, respectively, in patients without D-SMI (*p \<* 0.0001) ([Figure 3](#nutrients-09-00595-f003){ref-type="fig"}A). For females (*n =* 178), the one-, three-, and five-year cumulative OS rates were 93.6%, 87.7%, and 66.1%, respectively, in patients with D-SMI, and 98.3%, 92.4%, and 83.8%, respectively, in patients without D-SMI (*p =* 0.0056) ([Figure 3](#nutrients-09-00595-f003){ref-type="fig"}B).

Using ROC analysis for survival, the optimal cut-off point for SMI was 7.0 cm^2^/m^2^ in males (AUROC = 0.672, sensitivity = 64.6%, specificity = 69.4%) and 5.4 cm^2^/m^2^ in females (AUROC = 0.658, sensitivity = 45.7%, specificity = 83.9%). When the cut-off value of 5.4 cm^2^/m^2^ was adapted to our female patients (cut-off value for female in WAGS; 5.7 cm^2^/m^2^), similar results were obtained. That is, patients with D-SMI had significantly poorer survival rates than those without D-SMI (*p =* 0.0076).

3.3. Causes for Death for Males and Females {#sec3dot3-nutrients-09-00595}
-------------------------------------------

In male, during the observation period, 48 patients (23.4%) died. The causes for death were liver failure in 28 patients, HCC progression in 10 patients and miscellaneous causes in 10 patients. In female, during the observation period, 35 patients (19.7%) died. The causes for death were liver failure in 28 patients, HCC progression in four patients and miscellaneous causes in three patients.

3.4. Univariate and Multivariate Analyses of Parameters Contributing to OS for Males {#sec3dot4-nutrients-09-00595}
------------------------------------------------------------------------------------

Univariate analysis identified the following factors as significantly associated with OS for males: age (*p =* 0.0041); SMI (*p \<* 0.0001); Child-Pugh score (*p =* 0.0252); aspartate aminotransferase (*p =* 0.0150); alanine aminotransferase (ALT) (*p =* 0.0407); serum albumin (*p =* 0.0011); serum sodium (*p =* 0.0133); serum creatinine (*p =* 0.0088); and BMI (*p =* 0.0041) ([Table 2](#nutrients-09-00595-t002){ref-type="table"}a). Since the Child-Pugh score includes serum albumin, it was not entered into the multivariate analysis, and since age and BMI significantly correlated with SMI, they were also excluded in the multivariate analysis to avoid the effect of collinearity. The hazard ratios (HRs) and 95% confidence intervals (CIs) calculated by using multivariate analysis for the six significant variables (*p \<* 0.05) in the univariate analysis are presented in [Table 2](#nutrients-09-00595-t002){ref-type="table"}b. SMI (*p =* 0.0005) and Child-Pugh score (*p =* 0.0424) were found to be significant predictors related to OS in the multivariate analysis ([Table 2](#nutrients-09-00595-t002){ref-type="table"}b).

3.5. Univariate and Multivariate Analyses of Parameters Contributing to OS for Females {#sec3dot5-nutrients-09-00595}
--------------------------------------------------------------------------------------

Univariate analysis identified the following parameters as significantly associated with OS for females: age (*p =* 0.0214); SMI (*p =* 0.0076); Child-Pugh score (*p =* 0.0009); ALT (*p =* 0.0104); serum albumin (*p =* 0.0003); prothrombin time (PT) (*p =* 0.0355); platelet count (*p =* 0.0333); triglyceride (*p =* 0.0011); serum creatinine (*p =* 0.0137); BMI (*p =* 0.0270) and presence of ascites (*p \<* 0.0001) ([Table 3](#nutrients-09-00595-t003){ref-type="table"}a). As the Child-Pugh score includes serum albumin, PT, and ascites, they were not entered into the multivariate analysis, and because BMI significantly correlated with SMI, it was also excluded in the multivariate analysis to avoid the effect of collinearity. The HRs and 95% CIs calculated by using multivariate analysis for the seven significant variables (*p \<* 0.05) in the univariate analysis are presented in [Table 3](#nutrients-09-00595-t003){ref-type="table"}b. SMI (*p =* 0.0016) and Child-Pugh scores (*p \<* 0.0001) were found to be significant predictors related to OS in the multivariate analysis ([Table 3](#nutrients-09-00595-t003){ref-type="table"}b).

3.6. Time-Dependent ROC Analyses for OS in Males {#sec3dot6-nutrients-09-00595}
------------------------------------------------

Results for time-dependent ROC analyses at two-, three-, four-, five-, six-, and seven-years of SMI and the Child-Pugh scores for males are shown in [Figure 4](#nutrients-09-00595-f004){ref-type="fig"}A. All AUROCs for SMI at each time point were higher than those for Child-Pugh scores, denoting that SMI had consistently superior predictive ability for OS over Child-Pugh scores.

3.7. Time-Dependent ROC Analyses for OS in Females {#sec3dot7-nutrients-09-00595}
--------------------------------------------------

Results for time-dependent ROC analyses at two-, three-, four-, five-, six-, and seven-years of SMI and Child-Pugh score for female were shown in [Figure 4](#nutrients-09-00595-f004){ref-type="fig"}B. All AUROCs for Child-Pugh scores at each time point were higher than those for SMI, denoting that Child-Pugh scores had consistently superior predictive ability for OS over SMI.

3.8. Time-Dependent ROC Analyses for OS in Male Patients with Child-Pugh A {#sec3dot8-nutrients-09-00595}
--------------------------------------------------------------------------

Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for male Child-Pugh A patients (*n =* 148) are shown in [Figure 5](#nutrients-09-00595-f005){ref-type="fig"}A. All AUROCs for SMI in each time point were higher than those for Child-Pugh scores, denoting that SMI had consistently superior predictive ability for OS over Child-Pugh scores.

3.9. Time-Dependent ROC Analyses for OS in Female Patients with Child-Pugh A {#sec3dot9-nutrients-09-00595}
----------------------------------------------------------------------------

Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for female Child-Pugh A patients (*n =* 131) are shown in [Figure 5](#nutrients-09-00595-f005){ref-type="fig"}B. All AUROCs for Child-Pugh score in each time point were higher than those for SMI, denoting that Child-Pugh scores had consistently superior predictive ability for OS over SMI.

3.10. Time-Dependent ROC Analyses for OS in Male Patients with Child-Pugh B or C {#sec3dot10-nutrients-09-00595}
--------------------------------------------------------------------------------

Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for male Child-Pugh B or C patients (*n =* 57) are shown in [Figure 6](#nutrients-09-00595-f006){ref-type="fig"}A. All AUROCs for SMI at each time point were higher than those for Child-Pugh scores, denoting that SMI had consistently superior predictive ability for OS over Child-Pugh scores.

3.11. Time-Dependent ROC Analyses for OS in Female Patients with Child-Pugh B or C {#sec3dot11-nutrients-09-00595}
----------------------------------------------------------------------------------

Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for female Child-Pugh B or C patients (*n =* 47) are shown in [Figure 6](#nutrients-09-00595-f006){ref-type="fig"}B. At four- and five-years, Child-Pugh scores had higher AUROC than SMI.

4. Discussion {#sec4-nutrients-09-00595}
=============

To the best of our knowledge, this is the first comparative study in SMI and Child-Pugh scores on clinical outcomes in LC patients. The Child-Pugh scoring system is a well-established prognostic system in LC patients \[[@B5-nutrients-09-00595],[@B6-nutrients-09-00595],[@B7-nutrients-09-00595],[@B8-nutrients-09-00595],[@B9-nutrients-09-00595]\]. While, SMI in LC has been currently attracting much attention owing to its well predictive performance \[[@B14-nutrients-09-00595],[@B15-nutrients-09-00595],[@B16-nutrients-09-00595],[@B17-nutrients-09-00595],[@B19-nutrients-09-00595],[@B27-nutrients-09-00595],[@B28-nutrients-09-00595]\]. Investigation into the influence of SMI on outcomes in LC patients is pivotal and, particularly, clarifying which of these two markers has stronger predictive impact for LC is clinically essential in light of creating a novel prognostic system in LC patients. We, therefore, conducted this comparative analysis to address this question. Since skeletal muscle mass significantly can differ between male and female, we analyzed and discussed separately in males and females.

In our results, for males, SMI and Child-Pugh scores were revealed to be significant for OS in the multivariate analysis, and all AUROCs for SMI at each time point were higher than those for Child-Pugh scores. Additionally, in subgroup analyses for male patients with Child-Pugh A or Child-Pugh B or C, SMI had consistently higher AUROCs than the Child-Pugh score. For females, similar results were obtained in the multivariate analysis, however, all AUROCs for Child-Pugh scores at each time point were higher than those for SMI. These results denote that SMI as a predictor can perform well as compared with Child-Pugh score at least in male LC patients. Our current results may provide new information and shed some lights for the better comprehension of prognosis in LC patients. The significant difference in baseline characteristics in such as SMI, age, serum sodium, and serum creatinine between males and females can explain the different results according to gender. In particular, aging can be a significant predictor in LC patients \[[@B14-nutrients-09-00595],[@B39-nutrients-09-00595],[@B40-nutrients-09-00595]\]. Our country is an aging country \[[@B39-nutrients-09-00595],[@B40-nutrients-09-00595]\]. The reasons for results in time-dependent ROC analysis in females may be attributed to our results that SMI did not significantly correlate with age in females.

In view of our current results, some interventional therapies, including BCAA therapy, testosterone therapy, or exercise, can be considered especially in male LC patients with lower skeletal muscle mass for ameliorating prognosis \[[@B13-nutrients-09-00595],[@B35-nutrients-09-00595],[@B41-nutrients-09-00595],[@B42-nutrients-09-00595],[@B43-nutrients-09-00595]\]. However, firm recommendations for LC patients are not currently available. As for cut-off value for BIA, AWGS recommends 2SDs below the average muscle mass of young adults (7.0 cm^2^/m^2^ for male and 5.7 cm^2^/m^2^ for female) \[[@B28-nutrients-09-00595]\]. In our outcome based ROC analysis, the optimal cut-off points for survival were 7.0 cm^2^/m^2^ for males and 5.4 cm^2^/m^2^ for females, which were quite similar to recommendations in AWGS and their recommendations were well validated in our analysis. From the viewpoint of outcome-based analysis, our results may be worthy of reporting.

As described above, it is of note that SMI significantly correlated with age in males, but not in females. In general, changes in muscle mass occur with aging and muscle mass loss is a common condition which is recognized as a part of aging \[[@B44-nutrients-09-00595]\]. However, our results showed that the rates of muscle mass decline can vary according to gender, suggesting that factors other than aging, such as diet intake and lifestyle, may influence the maintenance of healthy muscle mass \[[@B45-nutrients-09-00595]\]. On the other hand, although the liver transplantation allocation system utilizes MELD score to prioritize organs to the most ill subjects, MELD scores do not perform better than Child-Pugh scores in non-transplant settings. In other words, MELD scores can perform well in decompensated LC rather than compensated LC \[[@B8-nutrients-09-00595]\]. Due to the high proportion of patients with Child-Pugh A in our cohort, we did not include MELD scores in the analysis.

Several limitations must be acknowledged in our current analysis. First, this study is a single-center retrospective observational study utilizing data for BIA and parameters reflecting muscle function such as hang grip strength or walking speed were not assessed in this analysis. In future studies, both skeletal muscle mass and muscle function should be evaluated in outcome based analyses. Second, patients with severe ascites were excluded from our analysis because SMI can be overestimated in these patients. Thus, the number of Child-Pugh C patients was rather small and our results cannot be adapted to such patients. Body composition analyses using BIA can be challenging in LC patients with severe ascites. Finally, various treatments for underlying liver diseases were performed during follow-up period in each patient, potentially creating bias. However, our study results denoted that SMI had higher predictive ability, at least in male LC patients. Results in time-dependent ROC analysis support our assertion for the predictive superiority of SMI over Child-Pugh scores in males.

In conclusion, SMI can be accessible for predicting outcomes, at least in male LC patients. Some interventions for male patients with lower SMI may be recommended.
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LC: liver cirrhosis; MELD: Model for End-stage Liver Disease; LT: liver transplantation; HCC: hepatocellular carcinoma; CT: computed tomography; MRI: magnetic resonance imaging; BIA: bioimpedance analysis; SMI: skeletal muscle mass index; BMI: body mass index; US: ultrasonography; BCAA: branched-chain amino acid; ROC: receiver operating characteristic curve; OS: overall survival; AUROC: area under the receiver operating characteristic curve; SD: standard deviation; AWGS: Asian Working Group for Sarcopenia criteria; D-SMI: decreased SMI; ALT: alanine aminotransferase; HR: hazard ratios; CI: confidence interval.
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![Cumulative overall survival for the entire cohort (*n =* 383). The one-, three-, and five-year cumulative OS rates were 92.7%, 82.4% and 59.2%, respectively, in patients with decreased SMI (D-SMI), and 97.2%, 92.2% and 84.4%, respectively, in patients without D-SMI (*p \<* 0.0001). D-SMI was defined according to the Asian Working Group for Sarcopenia criteria. The cut-off values for SMI are 7.0 kg/m^2^ for males and 5.7 kg/m^2^ for females. SMI: skeletal muscle mass index; D-SMI: decreased SMI.](nutrients-09-00595-g002){#nutrients-09-00595-f002}

![Cumulative overall survival for males (**A**) *n =* 205 and for females (**B**) *n =* 178 in patients with and without D-SMI. SMI: skeletal muscle mass index; D-SMI: decreased SMI.](nutrients-09-00595-g003){#nutrients-09-00595-f003}

![(**A**) Results for time-dependent ROC analyses at two-, three, four-, five-, six-, and seven-years of SMI and Child-Pugh scores for males; (**B**) Results for time-dependent ROC analyses at two-, three-, four-, five-, six-, and seven-years of SMI and Child-Pugh scores for females. ROC; receiver operating characteristics, AUROC; area under the ROC, SMI; skeletal muscle mass index, CP; Child-Pugh.](nutrients-09-00595-g004){#nutrients-09-00595-f004}

![(**A**) Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for male Child-Pugh A patients; (**B**) Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for female Child-Pugh A patients. ROC; receiver operating characteristics, AUROC; area under the ROC, SMI; skeletal muscle mass index.](nutrients-09-00595-g005){#nutrients-09-00595-f005}

![(**A**) Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh score for male Child-Pugh B or C patients; (**B**) Results for time-dependent ROC analyses at two-, three-, four-, and five-years of SMI and Child-Pugh scores for female Child-Pugh B or C patients. ROC; receiver operating characteristics, AUROC; area under the ROC, SMI; skeletal muscle mass index.](nutrients-09-00595-g006){#nutrients-09-00595-f006}

nutrients-09-00595-t001_Table 1

###### 

Baseline characteristics (*n =* 383).

  Variables                                 Number or Average ± SD   Male (*n =* 205)     Female (*n =* 178)   *p* Value (Male vs. Female)
  ----------------------------------------- ------------------------ -------------------- -------------------- -----------------------------
  Age (years)                               65.2 ± 10.3              64.1 ± 10.8          66.4 ± 9.5           0.0403
  Body mass index (kg/m^2^)                 23.3 ± 3.9               23.4 ± 3.8           23.2 ± 4.0           0.6028
  Skeletal muscle mass index (cm^2^/m^2^)   6.7 ± 1.1                7.4 ± 0.9            6.0 ± 0.7            \<0.0001
  Causes of liver disease                   32/235/116               22/122/61            10/113/55            0.2043
  Hepatitis B/Hepatitis C/others                                                                               
  Child-Pugh scores, 5/6/7/8/9/10/11        186/93/58/28/13/3/2      106/42/31/15/6/3/2   80/51/27/13/7/0/0    0.2587
  Total bilirubin (mg/dL)                   1.3 ± 1.1                1.3 ± 1.3            1.2 ± 0.7            0.2319
  Serum albumin (g/dL)                      3.7 ± 0.53               3.7 ± 0.54           3.6 ± 0.51           0.3897
  Prothrombin time (%)                      77.0 ± 13.8              77.5 ± 13.4          76.4 ± 14.2          0.4532
  Platelets (×10^4^/mm^3^)                  10.6 ± 5.5               10.5 ± 5.3           10.7 ± 5.7           0.8093
  Serum sodium (mmol/L)                     139.7 ± 2.5              139.3 ± 2.5          140.2 ± 2.6          0.0004
  Serum creatinine (mg/dL)                  0.74 ± 0.51              0.84 ± 0.65          0.62 ± 0.22          \<0.0001
  Total cholesterol (mg/dL)                 154.0 ± 36.8             152.8 ± 35.4         155.2 ± 38.4         0.5250
  Triglyceride (mg/dL)                      90.5 ± 45.1              95.5 ± 53.0          84.8 ± 33.0          0.2144
  AST (IU/L)                                49.3 ± 34.8              49.4 ± 32.3          49.2 ± 37.5          0.9417
  ALT (IU/L)                                42.6 ± 38.9              43.9 ± 34.2          41.0 ± 43.7          0.0951
  Fasting blood glucose (mg/dL)             110.9 ± 34.7             114.8 ± 39.9         106.4 ± 27.0         0.0101
  Ascites, yes/no                           44/339                   25/180               19/159               0.7484

Data are expressed as number or average ± standard deviation (SD). AST: aspartate aminotransferase; ALT: alanine aminotransferase.

nutrients-09-00595-t002_Table 2

###### 

(**a**) Univariate analyses of factors linked to overall survival for males (*n =* 205). (**b**) Multivariate analyses of factors linked to overall survival for male.

  -------------------------------------------- ----------------------------- ---------------- --------
  **(a)**                                                                                     
  **Variables**                                **Number of Each Category**   **Univariate**   
  ***p* Value**                                                                               
  Age (years) ≥ 70, yes/no                     91/114                        0.0041           
  Cause of liver diseases, B/C/others          22/122/61                     0.2746           
  SMI ≥ 7.0 cm^2^/m^2^, yes/no                 127/78                        \<0.0001         
  Child-Pugh score ≥ 6, yes/no                 99/106                        0.0252           
  AST ≥ 29 IU/L, yes/no                        146/59                        0.0150           
  ALT ≥ 47 IU/L, yes/no                        63/142                        0.0407           
  Serum albumin ≥ 3.7 g/dL, yes/no             113/92                        0.0011           
  Total bilirubin ≥ 2.0 mg/dL, yes/no          29/176                        0.1539           
  Prothrombin time ≥ 77.1%, yes/no             111/94                        0.4521           
  Platelet count ≥ 9.4 × 10^4^/mm^3^, yes/no   101/104                       0.2360           
  Total cholesterol ≥ 124 mg/dL, yes/no        165/40                        0.2398           
  Triglyceride ≥ 56 mg/dL, yes/no              170/35                        0.0649           
  Serum sodium ≥ 138 mmol/L, yes/no            166/39                        0.0133           
  Fasting blood glucose ≥ 97 mg/dL, yes/no     145/60                        0.4942           
  Serum creatinine ≥ 0.78 mg/dL, yes/no        84/121                        0.0088           
  Body mass index ≥ 23.4 kg/m^2^, yes/no       91/114                        0.0041           
  Ascites, yes/no                              25/180                        0.0712           
  **(b)**                                                                                     
  **Variables**                                **Multivariate Analysis**                      
  **Hazard Ratio**                             **95% CI**                    ***p* Value**    
  SMI (per one cm^2^/m^2^)                     0.571                         0.416--0.777     0.0005
  AST (per one IU/L)                           1.005                         0.987--1.022     0.5683
  ALT (per one IU/L)                           0.990                         0.972--1.008     0.3002
  Child-Pugh score (per one point)             1.270                         1.020--1.520     0.0424
  Serum sodium (per one mmol/L)                0.912                         0.807--1.033     0.1481
  Serum creatinine (per one mg/dL)             1.104                         0.769--1.397     0.4914
  -------------------------------------------- ----------------------------- ---------------- --------

CI: confidence interval; SMI: skeletal muscle mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
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###### 

(**a**) Univariate analyses of factors linked to overall survival for female (*n =* 178). (**b**) Multivariate analyses of factors linked to overall survival for female.

  ------------------------------------------- ----------------------------- ---------------- ----------
  **(a)**                                                                                    
  **Variables**                               **Number of Each Category**   **Univariate**   
  ***p* value**                                                                              
  Age (years) ≥ 77, yes/no                    22/156                        0.0214           
  Cause of liver diseases, B/C/others         10/113/55                     0.5037           
  SMI ≥ 5.4 cm^2^/m^2^, yes/no                139/39                        0.0076           
  Child-Pugh score ≥ 6, yes/no                98/80                         0.0009           
  AST ≥ 80 IU/L, yes/no                       20/158                        0.0544           
  ALT ≥ 58 IU/L, yes/no                       32/146                        0.0104           
  Serum albumin ≥ 3.4 g/dL, yes/no            117/61                        0.0003           
  Total bilirubin ≥ 2.3 mg/dL, yes/no         10/168                        0.7607           
  Prothrombin time ≥ 73.7%, yes/no            103/75                        0.0355           
  Platelet count ≥ 9.7 ×10^4^/mm^3^, yes/no   92/86                         0.0333           
  Total cholesterol ≥ 176 mg/dL, yes/no       49/129                        0.0558           
  Triglyceride ≥ 72 mg/dL, yes/no             108/70                        0.0011           
  Serum sodium ≥ 139 mmol/L, yes/no           143/35                        0.4064           
  Fasting blood glucose ≥ 89 mg/dL, yes/no    142/36                        0.2428           
  Serum creatinine ≥ 0.63 mg/dL, yes/no       66/112                        0.0137           
  Body mass index ≥ 23.4 kg/m^2^, yes/no      78/100                        0.0270           
  Ascites, yes/no                             19/159                        \<0.0001         
  **(b)**                                                                                    
  **Variables**                               **Multivariate Analysis**                      
  **Hazard ratio**                            **95% CI**                    ***p* Value**    
  Age (per one year)                          1.018                         0.977--1.063     0.3998
  SMI (per one cm^2^/m^2^)                    0.450                         0.270--0.731     0.0016
  ALT (per one IU/L)                          0.987                         0.967--1.107     0.0506
  Platelet count (per one × 10^4^/mm^3^)      0.919                         0.828--1.008     0.0943
  Child-Pugh score (per one point)            1.938                         1.400--2.690     \<0.0001
  Triglyceride (per one mg/dL)                0.998                         0.983--1.011     0.7760
  Serum creatinine (per one mg/dL)            2.546                         0.413--10.860    0.2545
  ------------------------------------------- ----------------------------- ---------------- ----------

CI: confidence interval; SMI: skeletal muscle mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
